CN1618957A - Human cholesteryl ester synthase-2b and its coding sequence - Google Patents

Abstract

The present invention provides cDNA sequence of human cholesteryl ester synthase-2b (ACAT2b) and its encoded amino acid sequence of human cholesteryl ester synthase, constructs and vectors containing the sequence, and their application. The nucleotide sequence of human ACAT2b cDNA is about 1.5kb long, encoding 502 amino acid sequences. The human ACAT2b cDNA and the human cholesteryl ester synthase encoded by the present invention can be used for the research and screening of drugs for the treatment or auxiliary treatment of hypercholesterolemia, atherosclerosis and the like.

Description

People's cholesteryl ester synthetic enzyme-2b and encoding sequence thereof

Invention field

The present invention relates to biological chemistry, molecular biology, genetically engineered and DNA recombinant technology field.More specifically, relate to people's cholesteryl ester synthetic enzyme-2b (ACAT2b) and encoding sequence thereof and their application.

Background technology

People's cholesteryl ester synthetic enzyme is a human acyl coenzyme A: cholesterol acyltransferase (ACAT; Acyl-coenzyme A:cholesterol acyltransferase; EC2.3.1.26), be the enzyme that interior unique catalysis longer chain fatty acid of people's cell and free cholesterol form cholesteryl ester.ACAT brings into play the important physical function in vivo, mainly participates in organism cholesterol and processes such as the absorption of ester class, transportation and storage thereof, is one of key enzyme of keeping body inner cholesterol and ester class metabolic balance thereof.Studies show that in a large number that both at home and abroad it is high reactivity ground synthetic cholesterol ester in scavenger cell, cause the excessive accumulation of cell inner cholesterol ester and form foam cell, cause atherosclerosis (AS) early lesion; Its activity cholesterol amount in the cytolemma that can affect the nerves, and directly regulate the generation a, relevant with senile dementia lesion (AD); Its activity change in liver, intestinal cells can directly influence the absorption of synthetic cholesterol ester, cholesterol, the assembling of lipoprotein, and is until blood levels that influences cholesterol and blood transhipment, directly related with hypercholesterolemia ester disease; And the absorption of chronic dietary source cholesterol lacks, and causes serious disease equally, as child, the dementia in old age etc.Therefore, it is epochmaking cholesterol metabolic relative disease drug target protein, in the world the main attack target protein of ACAT as development atherosclerosis pathology medicine.But ACAT is again the extremely low a kind of endoplasmic reticulum membranin of content, even long-term a large amount of people, the material resources etc. of dropping into of many in the world laboratories or company are studied, fails its natural type zymoprotein of purifying so far.So, carry out the work of gene level, to mechanism of action and the structure function of further investigation ACAT and with the relation of relative disease, seem very important, be present unique practicable approach.

In Mammals, find to have two kinds of different ACAT genes of coding ACAT1 and ACAT2 at present.1993, the people ACAT1 cDNA (4011bp) with active function was cloned in U.S. Dartmouth medical college Chang TY laboratory first, 550 aminoacid sequence (Chang TY et al. of its open reading frame coding, 1993, J.Biol.Chem., 268:20747-20755).1996, the experiment of mouse ACAT1 gene knockout was successfully carried out in the R.V.Farese laboratory of Univ California-San Francisco USA, and analyzed and find in liver and small intestine, still had strong ACAT enzymic activity, inferred the ACAT that has another kind of form thus.From Computer Analysis ACAT conserved sequence, 1998, three tame laboratories were cloned cercopithecus aethiops (Anderson RA et al., 1998 respectively, J.Biol.Chem., 273:26747-26754), mouse (Cases S et al., 1998, J.Biol.Chem., 273:26755-26764) and people (Oelkers P et al., 1998, J.Biol.Chem., ACAT2 cDNA 273:26765-26771).People ACAT2 cDNA is about 2040bp, 522 amino acid of its open reading frame coding.ACAT1 almost expresses in a organized way in institute, and ACAT2 have high expression level in liver and small intestine.Therefore, assembling and secretion that ACAT2 is considered to mainly to participate in the absorption of diet source cholesterol and contains the ApoB lipophorin, blood levels and blood direct and cholesterol are transported close association.

1999, the structure organization of people ACAT1 genomic dna is cooperated to have delivered with Chang TY laboratory in the contriver laboratory, and finder ACAT1 mRNA sequence comes from two different karyomit(e)s (Li Bo-Liang et al., J.Biol.Chem. respectively, 1999,274:11060-11071).Simultaneously, the contriver has carried out researchs such as people ACAT2 genomic dna structure organization again.In liver, intestinal cells, the contriver finds also to have another kind of ACAT2b cDNA form abroad except identical with the ACAT2 cDNA that is about 2040bp (systematic naming method is ACAT2a cDNA) that delivers of going together.The various ways of ACAT2 exists, and shows the importance and the complicacy of this gene function.

Change along with Chinese people's growth in the living standard and dietary structure, cardiovascular disorder and neural transformation disease more and more become the important killer who threatens people's life and health, and the research of massive epidemiology and molecular level has proved that these diseases and organism inner cholesterol level are closely related.Because ACAT has played keying action in cholesterol balance and the incidence of atherosclerosis process in vivo, the special inhibitor that therefore screens ACAT becomes the focus that some drugmakers are competitively studied.Because the ACAT albumen of natural form does not also have the purifying success, it is also very difficult therefore to seek the special effective inhibitors of ACAT.Increasing scientist and medical major company have participated in the research in this field both at home and abroad.Especially study the scientific research brainstrust of cardiovascular disorder, special hope can be screened the cardiovascular disease treating medicine of invention at atherosclerosis ACAT.Current paper is thought, the ACAT2 of liver, intestinal cells specifically expressing participates in the absorption of external source cholesterol and the assembling of lipoprotein, directly influence cholesterol levels in the blood, and be the medicine of effect target protein with ACAT2, can in control body's cholesterol level, not destroy intracellular cholesterol balance again, so the research of ACAT2 more and more is subject to people's attention.

The ACAT2b that the contriver finds, molecule mechanism for the critical function of illustrating ACAT and announcement hypercholesterolemia ester disease, atherosclerosis etc. is significant, this basic research breaks through, will very fast its action oriented research of initiation, and promote the invention of medicines such as cholesterol related diseases such as cardiovascular diseases rapidly.Yet, at present, also do not obtain people's cholesteryl ester synthetic enzyme aminoacid sequence of people ACAT2b cDNA and coding thereof.

Therefore, this area presses for people's cholesteryl ester synthetic enzyme of exploit person ACAT2b cDNA and coding thereof.

Summary of the invention

Purpose of the present invention just provides a kind of new people's cholesteryl ester synthetic enzyme 2b and encoding sequence thereof.

Another object of the present invention provides produces these people's cholesteryl ester synthetic enzyme and the method for encoding sequence and their purposes.

A first aspect of the present invention provides a kind of people's cholesteryl ester synthetic enzyme-2b, and described albumen is selected from down group:

(a) have albumen or its conservative property variant protein or its active fragments or its reactive derivative of SEQ ID NO:2 aminoacid sequence.

(b) SEQ ID NO:2 aminoacid sequence is formed through replacement, disappearance or the interpolation of one or more amino-acid residues, and have people's cholesteryl ester synthetic enzyme-2b function by (a) deutero-albumen.

In a preference, described people's cholesteryl ester synthetic enzyme-2b (ACAT2b) has the aminoacid sequence shown in the SEQ ID NO:2.

A second aspect of the present invention provides a kind of isolating polynucleotide, and described polynucleotide comprise one and are selected from down the nucleotide sequence of organizing:

(a) the above-mentioned proteic polynucleotide of coding;

(b) with polynucleotide (a) complementary polynucleotide.

Preferably, described polynucleotide encoding has the albumen of aminoacid sequence shown in the SEQ ID NO:2.

Preferable, the sequence of described polynucleotide comprises and is selected from down a kind of of group:

(a) sequence of 13-1521 position among the SEQ ID NO:1;

(b) sequence of 1-1522 position among the SEQ ID NO:1.

Better, the sequence of described polynucleotide has a kind of of the group of being selected from down:

(a) sequence of 13-1521 position among the SEQ ID NO:1;

(b) sequence of 1-1522 position among the SEQ ID No:1.

A third aspect of the present invention provides a kind of carrier, and described carrier contains above-mentioned polynucleotide.Preferable, described polynucleotide comprise 13-1521 bit sequence among the SEQ ID NO:1.

A fourth aspect of the present invention provides a kind of host cell, and described host cell comprises above-mentioned carrier.Preferably, described host cell is a mammalian cell.Better, described host cell is mouse, rat or people's a cell.

A fifth aspect of the present invention provides a kind of people's of having cholesteryl ester synthetic enzyme-2b active proteic preparation method, it is characterized in that this method comprises:

(a) under the condition that is fit to expressing human cholesteryl ester synthetic enzyme-2b, cultivate above-mentioned host cell;

(b) from culture, isolate and have the active albumen of people's cholesteryl ester synthetic enzyme-2b.

A sixth aspect of the present invention, provide a kind of can with above-mentioned people's cholesteryl ester synthetic enzyme-2b specificity bonded antibody.

A seventh aspect of the present invention provides a kind of pharmaceutical composition, and described pharmaceutical composition contains the above-mentioned people's cholesteryl ester synthetic enzyme-2b or the above-mentioned polynucleotide of safe and effective amount, and pharmaceutically acceptable carrier.

A eighth aspect of the present invention provides described people's cholesteryl ester synthetic enzyme-2b application in the medicine of screening or preparation treatment cholesterol related diseases.

A ninth aspect of the present invention provides the application of above-mentioned polynucleotide in the medicine of screening or preparation treatment cholesterol related diseases.

A tenth aspect of the present invention provides a kind of method of screening the medicine of treatment cholesterol related diseases, and described method comprises step:

(a) under the condition that is fit to growth, cultivate host cell, described host cell contains above-mentioned expression vector, described expression vector contains above-mentioned polynucleotide and the exogenous promoter that links to each other with this polynucleotide operability, wherein in the substratum of first group of host cell or lysate or preparation albumen, add candidate substances, in the substratum of second group of host cell or lysate or preparation albumen, do not add candidate substances;

(b) measure cholesteryl ester synthetic enzyme-2b activity in first group and second group of host cell or lysate or the preparation albumen, wherein first group of host cell or lysate or prepare proteic this enzymic activity and just represent that above and below second group this candidate substances is the medicine of treatment cholesterol related diseases.

Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.

Description of drawings

Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.

Fig. 1: people ACAT2b cDNA sequence is the polynucleotide encoding sequence of people's cholesteryl ester synthetic enzyme 2c.

Fig. 2: the aminoacid sequence of people's cholesteryl ester synthetic enzyme 2b.

Fig. 3: the recombinant expression vector and the western blot analysis that contain people ACAT2b encoding sequence:

A. the structure synoptic diagram of the recombinant expression vector of people ACAT2b encoding sequence;

B. the western blot analysis of people's cholesteryl ester synthetic enzyme 2b.

Fig. 4: the activation analysis of people's cholesteryl ester synthetic enzyme of people ACAT2b genetic expression.

Embodiment

The inventor is through extensive and deep research, separating clone obtains people ACAT2b cDNA first, and it is analyzed, determine a kind of people's cholesteryl ester synthetic enzyme aminoacid sequence of this cDNA coding, make up the recombinant expression vector of people ACAT2b cDNA, transfection mammalian cell is expressed, in order to the enzymic activity of analyst ACAT2b.Finished the present invention on this basis.

As used herein, term " cholesteryl ester synthetic enzyme-2b ", " ACAT2b " are used interchangeably, and refer to have the enzyme of ACAT2b aminoacid sequence (Fig. 2); Term " cholesteryl ester synthetic enzyme-2b cDNA ", " ACAT2b cDNA " " cholesteryl ester synthetic enzyme-2c gene " " ACAT2c gene " are used interchangeably, and refer to have the polymerized nucleoside acid sequence (Fig. 1, SEQ NO:1) of coding ACAT2b aminoacid sequence.

In the present invention, " cholesteryl ester synthetic enzyme-2b conservative property variation polypeptide " refers to compare with the aminoacid sequence of SEQ ID NO:2, has 10 at the most, preferably at the most 8, more preferably at the most 5,3 amino acid is replaced by similar performance or close amino acid and is formed polypeptide at the most best.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:1 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that in the present invention coding has the protein of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:1.

The polynucleotide of the mature polypeptide of coding SEQ ID NO:2 comprise: the encoding sequence of an encoding mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

The invention still further relates to the polynucleotide varient of above-mentioned cDNA.The varient that allelic variant that these polynucleotide varients can be natural generations or non-natural take place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of this cDNA in fact.

The invention still further relates to nucleic acid fragment with above-mentioned sequence hybridization.As used herein, the length of " nucleic acid fragment " contains 10 Nucleotide at least, better is at least 50 Nucleotide, is more preferably at least 100 Nucleotide, preferably at least 200 above total lengths to people's cholesteryl ester synthetic enzyme-2b cDNA of Nucleotide.Nucleic acid fragment can be used for the nucleotide sequence of amplification technique (as PCR) to determine and/or to clone cDNA of the present invention of nucleic acid.

The Nucleotide full length sequence of people ACAT2b cDNA of the present invention or its fragment can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention relevant nucleotide sequence design primer, and the cDNA library in personnel selection cell source or the cDNA library that contains the human chromosome cell be as template, amplification and must relevant sequence.

In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.

In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually, by first synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.At present, can be fully obtain the dna sequence dna of gene of the present invention (or its fragment, or derivatives thereof) by chemosynthesis.This dna sequence dna can be introduced in various existing dna moleculars as known in the art (or as carrier) and the cell then.

The method of application round pcr DNA amplification/RNA (Saiki RK et al., Science, 1985,230:1350-1354) be optimized for acquisition cDNA of the present invention.

The present invention also relates to comprise the construction or the carrier of gene of the present invention, and transform or the host cell of transduction with described construction or carrier, and the method that produces ATAC2b through recombinant technology.

Be applicable to that exogenous promoter of the present invention is not particularly limited, nearly all exogenous promoter all can be used for the present invention.The example of representational exogenous promoter comprises (but being not limited to): various recombinant clone promotors, and as promotor of SV40 promotor, CMV promotor etc. and various synthetic etc.It should be noted that exogenous promoter also comprises the promotor from host itself.For example, for some inherited disease the disease that high reactivity or low activity caused of certain promotor (for example because of), can separate from patient itself and obtain relevant promotor, then it is linked to each other with cholesteryl ester synthetic enzyme of the present invention-2bcDNA sequence, formation contains the construction of exogenous promoter, then described construction is used to screen the medicine of treatment cholesterol related diseases or be used for gene therapy.

The exogenous promoter that a kind of example of construction is exactly with the cholesteryl ester synthetic enzyme-2b cDNA links to each other.As for the position relation of cholesteryl ester synthetic enzyme-2b cDNA and exogenous promoter, the cDNA sequence should be positioned at the downstream of exogenous promoter.

Among the present invention, the nucleotide sequence of the people's cholesteryl ester synthetic enzyme-2b cDNA that contains can preferably be inserted into carrier, for example in the expression vector.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carriers.The carrier of Shi Yonging includes but not limited in the present invention: expression vector, cloning vector for example are applicable to the carrier in protokaryon (as bacteriums such as intestinal bacteria), eucaryon (as yeast), insect cell, vegetable cell, the mammalian cell.In a word, as long as can duplicate in host and stablize, any plasmid and carrier can be used.In expression vector, except containing replication orgin, cholesteryl ester synthetic enzyme-2b cDNA, also can contain controlling elementss such as exogenous promoter is transcribed with other, translation.

Method well-known to those having ordinary skill in the art can be used to make up and contains cholesteryl ester synthetic enzyme-2b cDNA and suitable transcribing/the translate expression vector of control signal.These methods comprise (Sambroook, et al.Molecular Cloning, a Laboratory Manual, Cold SpringHarbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can be effectively be connected with exogenous promoter to be expressed, and is synthetic to instruct described cDNA and corresponding mRNA.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance.

Comprise the carrier of suitable sequence and suitable promotor or the control sequence of people's cholesteryl ester synthetic enzyme-2b cDNA, can be used to transform appropriate host cell, so that it can expressing human cholesteryl ester synthetic enzyme-2b.

Host cell can be a prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; The bacterial cell of Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; The insect cell of fruit bat S2 or Sf9; The zooblast of CHO, COS, 293 cells or Bowes melanoma cells etc.The preferred mammal cell, as mouse, rat and people's cell.

Can carry out with routine techniques well known to those skilled in the art with the recombinant DNA transformed host cell.The method for transformation of some employings includes, but are not limited to: coprecipitation of calcium phosphate method, conventional mechanical method such as microinjection, electroporation, liposome packing etc.

The transformant that obtains can be cultivated with ordinary method, to express ACAT2b.According to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth and expresses, cultivate.The extracellular can be expressed or be secreted into to above-mentioned recombinant polypeptide in cell or on cytolemma.

The present invention also comprises ACAT2b DNA or the polypeptide of its fragment coding has specific polyclonal antibody and monoclonal antibody, especially monoclonal antibody.Here, " specificity " is meant that antibody capable is incorporated into ACAT2b gene product or fragment.The present invention also comprises having immunocompetent antibody fragment, as Fab ' or (Fab) ₂Fragment; Heavy chain of antibody; Light chain of antibody; Or chimeric antibody, as have the murine antibody binding specificity but still keep antibody from people's antibody moiety.Antibody of the present invention can be prepared by the known various technology of those skilled in that art.

The antibody of anti-ACAT2b can be used in the immunohistochemistry technology, detects the ACAT2b in the biopsy specimen.Utilize albumen of the present invention,, can filter out with ACAT2b interactional material takes place, as inhibitor, agonist or antagonist etc. by various conventional screening methods.

The present invention also provides a kind of pharmaceutical composition, and it contains ACAT2b of the present invention, its coding nucleic acid and/or the antisense nucleic acid of safe and effective amount, and pharmaceutically acceptable carrier or vehicle.This class carrier comprises (but being not limited to): salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.Pharmaceutical composition of the present invention can be made into the injection form, for example is prepared by ordinary method with the physiological saline or the aqueous solution that contains glucose and other assistant agents.Pharmaceutical composition such as tablet and capsule can be prepared by ordinary method.Pharmaceutical composition such as injection, solution, tablet and capsule should be made under aseptic condition.The dosage of activeconstituents is the treatment significant quantity, for example every day about 0.01 microgram/kg body weight-Yue 5 mg/kg body weight.In addition, polypeptide of the present invention also can use with the other treatment agent.

When making pharmaceutical composition, be that the ACAT2b of safe and effective amount or its antagonist, agonist are applied to Mammals, wherein this safe and effective amount is usually at least about 0.01 microgram/kg body weight, and in most of the cases be no more than about 10 mg/kg body weight, preferably this dosage is about 0.01 microgram/kg body weight-Yue 100 micrograms/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.

The invention still further relates to the diagnostic testing process of quantitative and detection and localization ACAT2b level.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The ACAT2b level that is detected in the test can be with laying down a definition the importance of ACAT2b in various diseases and be used to diagnose ACAT2b to lack as or increase caused disease.

The method that whether has ACAT2b in a kind of test sample is to utilize the specific antibody of ACAT2b to detect, and it comprises: sample is contacted with the ACAT2b specific antibody; Observe whether form antibody complex, formed antibody complex and just represented to exist in the sample ACAT2b.

In one embodiment of the invention, obtained people ACAT2b cDNA sequence by pcr amplification, analyze simultaneously and find that this cDNA sequence 5 '-zone has the ATG translation initiation codon, 3 '-zone has TAG translation stop codon, illustrate that this is to have the gene cDNA sequence that frame is read in typical case's translation, a kind of people's cholesteryl ester synthetic enzyme of 502 aminoacid sequences of its coding is ACAT2b.

In another embodiment, the present invention is with the expression vector of people ACAT2b cDNA, transfection mammalian cell is expressed, analyzed the cholesteryl ester synthetase albumen that people ACAT2b cDNA expresses, utilize two kinds of systems approaches of Cell-free and Intact cell to measure the cholesteryl ester synthase activity simultaneously, show that transfectional cell expressing human ACAT2b has the cholesteryl ester synthase activity, but far below the positive control activity, show its diagnosis and treatment, drug research, have extremely important value cholesterol metabolic relative diseases such as hypercholesterolemia ester diseases.

Cholesteryl ester synthetic enzyme of the present invention-2b cDNA has broad application prospects.ACAT-2b is still significant to diagnosis, treatment and the drug screening of cholesterol related diseases (comprising atherosclerosis, Alzheimer's disease etc.) to fundamental research.The present invention makes may be by changing the expression activity of ACAT in specific period, particular organization, for treatment cholesterol metabolic relative disease (as atherosclerosis etc.) provides another possible approach, and can utilize the present invention in mammalian cell, to express ACAT-2b.

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, people such as Sambrook for example, molecular cloning: laboratory manual (New York:Cold Spring HarborLaboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.

Clone, the evaluation of embodiment 1 people ACAT2b cDNA

For obtaining to contain people ACAT2b cDNA sequence, design synthetic primer, sequence is as follows:

C41：5’GGAGACCGCACCATGGAG3’

C42：5’TGTCTAGACCTCTAGGTATGGCAGGAC3’

C21：5’GGAAGAGTATCAGCATGACG3’

Use C41 and C42, C41 and two pairs of primers of C21 respectively, utilize the cDNA product of RT-PCR amplification HepG2 and Caco-2 cell, the PCR product cloning is arrived T-Easy Vector (available from Promega), order-checking and analytical sequence, discovery has 502 a kind of cDNA sequences of amino acid whose people's cholesteryl ester synthetic enzyme of coding, called after ACAT2b gene order.

The nucleotide sequence of the people ACAT2b cDNA that records is shown in Fig. 1 and SEQ ID NO:1.

Embodiment 2 people ACAT2b cDNA read frame and encoding amino acid sequence analysis thereof

The ACAT2b cDNA sequence that obtains according to order-checking, analyze and find that this cDNA sequence 5 '-zone has the ATG translation initiation codon, 3 '-zone has TAG translation stop codon, illustrate that this is to have the gene cDNA sequence that frame is read in typical case's translation, people's cholesteryl ester synthetic enzyme of 502 aminoacid sequences of its coding is ACAT2b (Fig. 2), and the people ACAT2a that reports than external colleague lacks 20 amino acid residue sequences.

Embodiment 3 people ACAT2b cDNA Construction of eukaryotic

For determining protein expression and the enzyme activity assay of people ACAT2b cDNA, utilize total RNA earlier from people's intestinal cells strain Caco-2 preparation, obtain document by the RT-PCR amplification and deliver the coding region of ACAT2 cDNA sequence as positive (Positive) contrast; Then, the positive control and the sample cDNA that obtain are inserted respectively between the EcoRV and XbaI of pcDNA3 (available from Invitrogene company), be positioned at the downstream of CMV promotor, obtain corresponding carrier for expression of eukaryon: pcDNA3-A2 and pcDNA3-A2b (referring to Fig. 3 top line chart spectrum).

Embodiment 4 cell cultures, DNA transfection and people ACAT2b cDNA expressed protein are analyzed

Utilize the Chinese hamster ovary celI strain AC29 of a strain ACAT defective type, in F12 substratum (containing 10%FBS, 100 μ g/mlstreptomycin, 100 μ g/ml penicillin), in humidity 95%, 5%CO ₂, 37 ℃ cultivate down.The expression analysis of people ACAT2b cDNA proteins encoded determines that by transfection experiment the method for selecting for use is coprecipitation of calcium phosphate method (Calcium-phosphate transfection, Liu J et al.1997).With carrier pcDNA3 (Negative contrast), pcDNA3-A2 (Positive contrast) and three kinds of plasmid DNA of pcDNA3-A2b, AC29 carries out expression study with the strain of calcium phosphate method transfection ACAT defective type Chinese hamster ovary celI respectively.

Concrete experimentation is as follows: transfection seeds cells among the 60mm dish the day before yesterday, and every dish cell count is 500,000/5ml, and the cell abundance reaches 30-50% during transfection.Transfection renewed bright substratum in preceding 3 hours.Preparation calcium phosphate precipitation plasmid DNA comprises 12 μ g sample plasmid DNA (each dish), dropwise DNA/ calcium phosphate precipitation liquid is added in the training liquid 37 ℃ of transfection AC29 cells then.After 10 hours, PBS washes cell 2 times, recovers growth in fresh culture.Collect cells transfected after 48 hours.

It is as follows that collecting cell is measured protein expression: the transfectional cell of cultivation washes twice with cold PBS, adds 100 μ l cell pyrolysis liquids (10%SDS, 50mM Tris-HCl pH6.8,1mM EDTA, 25mM DTT) dissolved cell protein.The lysis protein solution is sheared for several times with No. 18 syringe needles, with fracture heavy-gravity chromosomal DNA.Determining the protein quantity carries out according to Lowry method slightly modified.SDS-PAGE analyzes and carries out according to the Laemmli method, and gum concentration is 12%.After electrophoresis finished, polyacrylamide gel-4 a layer electricity that shifts filter paper-nitrocellulose filter-electricity commentaries on classics damping fluid rinsing of spreading 4 layers of electrotransfer liquid on the instrument from bottom to up respectively and soaking at running gel changeed the filter paper that liquid soaks, and sets electric current 1mA/cm ²Shifted 30 minutes.Nitrocellulose filter that transfer finishes after 30 minutes, adds the DM54 ACAT2 antibody mulch film of dilution with the TBST damping fluid sealing that contains 5% skim-milk, and 4 ℃ are shaken and spend the night or room temperature 2 hours.The TBST damping fluid is washed film 3 times.The goat anti-rabbit igg mulch film that adds the horseradish peroxidase-labeled of dilution then, room temperature 1 hour, the TBST damping fluid is washed film 3 times, and the TBS damping fluid is washed film 2 times.Carry out fluorography by the method that ECL Western blot detection kit (Santa CruzBiotechnology Inc. company) provides, the result is referring to Fig. 3 below.

The enzyme activity assay of embodiment 5 cell cultures, DNA transfection and people ACAT2b cDNA expressing protein

Cell cultures, DNA transfection experiment carry out two kinds of systems approaches of Cell-free and IntactCell then respectively and measure the cholesteryl ester synthase activity substantially with above-mentioned embodiment 4.

The analysis reference literature reported method of Cell free systems measurement cholesteryl ester synthase activity (Chang CCYet al., 1995, J.Biol.Chem.270:29532-29540), the cracking transfectional cell, add cholesterol and ³The oleoyl CoA substrate of H mark, the enzymic activity of ACAT in the mensuration microsome.Specific practice is, the transfection AC29 cell that cold PBS washes after twice adds the 1mM Tris (pH7.8) that 100 μ l contain 1mM EDTA, place collecting cell lysate after 5 minutes on ice, get 15 μ l 2M KCl, 7.5 μ l 10%CHAPS, 37 ℃ of effects of 15 μ l cell lysates and reaction substrate 10 minutes add 4ml CHCl3: MeOH (2: 1) mixing termination reaction then, add 10 μ l oleoyl cholesterol again, mixing, add 1ml water, centrifugal, abandon water, dry up, add 60 μ l ethyl acetates, thin-layer chromatography is collected cholesterol ester, isotropic substance is counted, and proofreaies and correct the expression amount of ACAT2b with Western blot.This method records ACAT2b and has the cholesteryl ester synthase activity, but far below positive control (referring to Fig. 4 A).

Analysis reference literature reported method (Chang CCYet al., 1986, Biochemistry, the 25:1700-1705 of Intact Cell systems measurement cholesteryl ester synthase activity; Cadigan KM et al., 1988, J.Biol.Chem. 263:274-82) carries out.Concise and to the point way is that the AC29 cell after the transfection adds ³The oleic acid of H mark was cultivated 3-4 hour, regathered cell and cracking, measured cell inner cholesterol fat synthetic (CE is synthetic) at last, and proofreaied and correct the expression amount of ACAT2b with Westernblot.This method records ACAT2b and has the cholesteryl ester synthase activity, also far below positive control (referring to Fig. 4 B).

All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.

Sequence table

＜110〉Shanghai Inst. of Life Science, CAS

＜120〉people's cholesteryl ester synthetic enzyme-2b and encoding sequence thereof

<130>031115b

<160>5

<170>PatentIn?version?3.1

<210>1

<211>1522

<212>DNA

＜213〉homo sapiens

<220>

<221>CDS

<222>(13)..(1521)

<223>

<400>1

ggagaccgca?cc?atg?gag?cca?ggc?ggg?gcc?cgt?ctg?cgt?ctg?cag?agg?aca 51

Met?Glu?Pro?Gly?Gly?Ala?Arg?Leu?Arg?Leu?Gln?Arg?Thr

1 5 10

gaa?ggg?ctg?gga?ggg?gag?cgg?gag?cgc?caa?ccc?tgt?gga?gat?gga?aac 99

Glu?Gly?Leu?Gly?Gly?Glu?Arg?Glu?Arg?Gln?Pro?Cys?Gly?Asp?Gly?Asn

15 20 25

act?gag?acg?cac?aga?gcc?ccg?gac?ttg?gta?caa?tgg?acc?cga?cac?atg 147

Thr?Glu?Thr?His?Arg?Ala?Pro?Asp?Leu?Val?Gln?Trp?Thr?Arg?His?Met

30 35 40 45

gag?gct?gtg?aag?gca?caa?ttg?ctg?gag?caa?gcg?cag?gga?caa?ctg?agg 195

Glu?Ala?Val?Lys?Ala?Gln?Leu?Leu?Glu?Gln?Ala?Gln?Gly?Gln?Leu?Arg

50 55 60

gag?ctg?ctg?gat?cgg?gcc?atg?cgg?gag?gct?ata?caa?tcc?tac?cca?tca 243

Glu?Leu?Leu?Asp?Arg?Ala?Met?Arg?Glu?Ala?Ile?Gln?Ser?Tyr?Pro?Ser

65 70 75

caa?gac?aaa?cct?ctg?ccc?cca?cct?ccc?cca?ggt?tcc?ttg?agc?agt?gag 291

Gln?Asp?Lys?Pro?Leu?Pro?Pro?Pro?Pro?Pro?Gly?Ser?Leu?Ser?Ser?Glu

80 85 90

ctg?atg?gag?gtg?cag?cat?ttc?cgc?acc?atc?tac?cac?atg?ttc?atc?gct 339

Leu?Met?Glu?Val?Gln?His?Phe?Arg?Thr?Ile?Tyr?His?Met?Phe?Ile?Ala

95 100 105

ggc?ctg?tgt?gtc?ttc?atc?atc?agc?acc?ctg?gcc?atc?gac?ttc?att?gat 387

Gly?Leu?Cys?Val?Phe?Ile?Ile?Ser?Thr?Leu?Ala?Ile?Asp?Phe?Ile?Asp

110 115 120 125

gag?ggc?agg?ctg?ctg?ctg?gag?ttt?gac?cta?ctg?atc?ttc?agc?ttc?gga 435

Glu?Gly?Arg?Leu?Leu?Leu?Glu?Phe?Asp?Leu?Leu?Ile?Phe?Ser?Phe?Gly

130 135 140

cag?ctg?cca?ttg?gcg?ctg?gtg?acc?tgg?gtg?ccc?atg?ttt?ctg?tcc?acc 483

Gln?Leu?Pro?Leu?Ala?Leu?Val?Thr?Trp?Val?Pro?Met?Phe?Leu?Ser?Thr

145 150 155

ctg?ttg?gcg?ccg?tac?caa?gcc?cta?cgg?ctg?tgg?gcc?agg?ggc?acc?tgg 531

Leu?Leu?Ala?Pro?Tyr?Gln?Ala?Leu?Arg?Leu?Trp?Ala?Arg?Gly?Thr?Trp

160 165 170

acg?cag?gcg?acg?ggc?ctg?ggc?tgt?gcg?ctg?cta?gcc?gcc?cac?gcc?gtg 579

Thr?Gln?Ala?Thr?Gly?Leu?Gly?Cys?Ala?Leu?Leu?Ala?Ala?His?Ala?Val

175 180 185

gtg?ctc?tgc?gcg?ctg?ccg?gtc?cac?gtg?gcc?gtg?gag?cat?cag?ctc?ccg 627

Val?Leu?Cys?Ala?Leu?Pro?Val?His?Val?Ala?Val?Glu?His?Gln?Leu?Pro

190 195 200 205

ccg?gcc?tcc?cgt?tgt?gtc?ctg?gtc?ttc?gag?cag?ggt?agg?ttc?ctg?atg 675

Pro?Ala?Ser?Arg?Cys?Val?Leu?Val?Phe?Glu?Gln?Gly?Arg?Phe?Leu?Met

210 215 220

aaa?agc?tac?tcc?ttc?ctg?aga?gag?gct?gtg?cct?ggg?acc?ctt?cgt?gcc 723

Lys?Ser?Tyr?Ser?Phe?Leu?Arg?Glu?Ala?Val?Pro?Gly?Thr?Leu?Arg?Ala

225 230 235

aga?cga?ggt?gag?ggg?atc?cag?gcc?ccc?agt?ttc?tcc?agc?tac?ctc?tac 771

Arg?Arg?Gly?Glu?Gly?Ile?Gln?Ala?Pro?Ser?Phe?Ser?Ser?Tyr?Leu?Tyr

240 245 250

ttc?ctc?ttc?tgc?cca?aca?ctc?atc?tac?agg?gag?act?tac?cct?agg?acg 819

Phe?Leu?Phe?Cys?Pro?Thr?Leu?Ile?Tyr?Arg?Glu?Thr?Tyr?Pro?Arg?Thr

255 260 265

ccc?tat?gtc?agg?tgg?aat?tat?gtg?gcc?aag?aac?ttt?gcc?cag?gcc?ctg 867

Pro?Tyr?Val?Arg?Trp?Asn?Tyr?Val?Ala?Lys?Asn?Phe?Ala?Gln?Ala?Leu

270 275 280 285

gga?tgt?gtg?ctc?tat?gcc?tgc?ttc?atc?ctg?ggc?cgc?ctc?tgt?gtt?cct 915

Gly?Cys?Val?Leu?Tyr?Ala?Cys?Phe?Ile?Leu?Gly?Arg?Leu?Cys?Val?Pro

290 295 300

gtc?ttt?gcc?aac?atg?agc?cga?gag?ccc?ttc?agc?acc?cgt?gcc?ctg?gtg 963

Val?Phe?Ala?Asn?Met?Ser?Arg?Glu?Pro?Phe?Ser?Thr?Arg?Ala?Leu?Val

305 310 315

ctc?tct?atc?ctg?cac?gcc?acg?ttg?cca?ggc?atc?ttc?atg?ctg?ctg?ctc 1011

Leu?Ser?Ile?Leu?His?Ala?Thr?Leu?Pro?Gly?Ile?Phe?Met?Leu?Leu?Leu

320 325 330

atc?ttc?ttt?gcc?ttc?ctc?cat?tgc?tgg?ctc?aac?gcc?ttt?gcc?gag?atg 1059

Ile?Phe?Phe?Ala?Phe?Leu?His?Cys?Trp?Leu?Asn?Ala?Phe?Ala?Glu?Met

335 340 345

cta?cga?ttt?gga?gac?agg?atg?ttc?tac?cgg?gac?tgg?tgg?aac?tca?acg 1107

Leu?Arg?Phe?Gly?Asp?Arg?Met?Phe?Tyr?Arg?Asp?Trp?Trp?Asn?Ser?Thr

350 355 360 365

tcc?ttc?tcc?aac?tac?tac?cgc?act?tgg?aac?gtg?gtg?gtc?cat?gac?tgg 1155

Ser?Phe?Ser?Asn?Tyr?Tyr?Arg?Thr?Trp?Asn?Val?Val?Val?His?Asp?Trp

370 375 380

ctg?tac?agc?tac?gtg?tat?cag?gat?ggg?ctg?cgg?ctc?ctt?ggt?gcc?cgg 1203

Leu?Tyr?Ser?Tyr?Val?Tyr?Gln?Asp?Gly?Leu?Arg?Leu?Leu?Gly?Ala?Arg

385 390 395

gcc?cga?ggg?gta?gcc?atg?ctg?ggt?gtg?ttc?ctg?gtc?tcc?gca?gtg?gcc 1251

Ala?Arg?Gly?Val?Ala?Met?Leu?Gly?Val?Phe?Leu?Val?Ser?Ala?Val?Ala

400 405 410

cat?gag?tat?atc?ttc?tgc?ttc?gtc?ctg?ggg?ttc?ttc?tat?ccc?gtc?atg 1299

His?Glu?Tyr?Ile?Phe?Cys?Phe?Val?Leu?Gly?Phe?Phe?Tyr?Pro?Val?Met

415 420 425

ctg?ata?ctc?ttc?ctt?gtc?att?gga?gga?atg?ttg?aac?ttc?atg?atg?cat 1347

Leu?Ile?Leu?Phe?Leu?Val?Ile?Gly?Gly?Met?Leu?Asn?Phe?Met?Met?His

430 435 440 445

gac?cag?cgc?acc?ggc?ccg?gca?tgg?aac?gtg?ctg?atg?tgg?acc?atg?ctg 1395

Asp?Gln?Arg?Thr?Gly?Pro?Ala?Trp?Asn?Val?Leu?Met?Trp?Thr?Met?Leu

450 455 460

ttt?cta?ggc?cag?gga?atc?cag?gtc?agc?ctg?tac?tgc?cag?gag?tgg?tac 1443

Phe?Leu?Gly?Gln?Gly?Ile?Gln?Val?Ser?Leu?Tyr?Cys?Gln?Glu?Trp?Tyr

465 470 475

gca?cgg?cgg?cac?tgc?ccc?tta?ccc?cag?gca?act?ttc?tgg?ggg?ctg?gtg 1491

Ala?Arg?Arg?His?Cys?Pro?Leu?Pro?Gln?Ala?Thr?Phe?Trp?Gly?Leu?Val

480 485 490

aca?cct?cga?tct?tgg?tcc?tgc?cat?acc?tag?a 1522

Thr?Pro?Arg?Ser?Trp?Ser?Cys?His?Thr

495 500

<210>2

<211>502

<212>PRT

＜213〉homo sapiens

<400>2

Met?Glu?Pro?Gly?Gly?Ala?Arg?Leu?Arg?Leu?Gln?Arg?Thr?Glu?Gly?Leu

1 5 10 15

Gly?Gly?Glu?Arg?Glu?Arg?Gln?Pro?Cys?Gly?Asp?Gly?Asn?Thr?Glu?Thr

20 25 30

His?Arg?Ala?Pro?Asp?Leu?Val?Gln?Trp?Thr?Arg?His?Met?Glu?Ala?Val

35 40 45

Lys?Ala?Gln?Leu?Leu?Glu?Gln?Ala?Gln?Gly?Gln?Leu?Arg?Glu?Leu?Leu

50 55 60

Asp?Arg?Ala?Met?Arg?Glu?Ala?Ile?Gln?Ser?Tyr?Pro?Ser?Gln?Asp?Lys

65 70 75 80

Pro?Leu?Pro?Pro?Pro?Pro?Pro?Gly?Ser?Leu?Ser?Ser?Glu?Leu?Met?Glu

85 90 95

Val?Gln?His?Phe?Arg?Thr?Ile?Tyr?His?Met?Phe?Ile?Ala?Gly?Leu?Cys

100 105 110

Val?Phe?Ile?Ile?Ser?Thr?Leu?Ala?Ile?Asp?Phe?Ile?Asp?Glu?Gly?Arg

115 120 125

Leu?Leu?Leu?Glu?Phe?Asp?Leu?Leu?Ile?Phe?Ser?Phe?Gly?Gln?Leu?Pro

130 135 140

Leu?Ala?Leu?Val?Thr?Trp?Val?Pro?Met?Phe?Leu?Ser?Thr?Leu?Leu?Ala

145 150 155 160

Pro?Tyr?Gln?Ala?Leu?Arg?Leu?Trp?Ala?Arg?Gly?Thr?Trp?Thr?Gln?Ala

165 170 175

Thr?Gly?Leu?Gly?Cys?Ala?Leu?Leu?Ala?Ala?His?Ala?Val?Val?Leu?Cys

180 185 190

Ala?Leu?Pro?Val?His?Val?Ala?Val?Glu?His?Gln?Leu?Pro?Pro?Ala?Ser

195 200 205

Arg?Cys?Val?Leu?Val?Phe?Glu?Gln?Gly?Arg?Phe?Leu?Met?Lys?Ser?Tyr

210 215 220

Ser?Phe?Leu?Arg?Glu?Ala?Val?Pro?Gly?Thr?Leu?Arg?Ala?Arg?Arg?Gly

225 230 235 240

Glu?Gly?Ile?Gln?Ala?Pro?Ser?Phe?Ser?Ser?Tyr?Leu?Tyr?Phe?Leu?Phe

245 250 255

Cys?Pro?Thr?Leu?Ile?Tyr?Arg?Glu?Thr?Tyr?Pro?Arg?Thr?Pro?Tyr?Val

260 265 270

Arg?Trp?Asn?Tyr?Val?Ala?Lys?Asn?Phe?Ala?Gln?Ala?Leu?Gly?Cys?Val

275 280 285

Leu?Tyr?Ala?Cys?Phe?Ile?Leu?Gly?Arg?Leu?Cys?Val?Pro?Val?Phe?Ala

290 295 300

Asn?Met?Ser?Arg?Glu?Pro?Phe?Ser?Thr?Arg?Ala?Leu?Val?Leu?Ser?Ile

305 310 315 320

Leu?His?Ala?Thr?Leu?Pro?Gly?Ile?Phe?Met?Leu?Leu?Leu?Ile?Phe?Phe

325 330 335

Ala?Phe?Leu?His?Cys?Trp?Leu?Asn?Ala?Phe?Ala?Glu?Met?Leu?Arg?Phe

340 345 350

Gly?Asp?Arg?Met?Phe?Tyr?Arg?Asp?Trp?Trp?Asn?Ser?Thr?Ser?Phe?Ser

355 360 365

Asn?Tyr?Tyr?Arg?Thr?Trp?Asn?Val?Val?Val?His?Asp?Trp?Leu?Tyr?Ser

370 375 380

Tyr?Val?Tyr?Gln?Asp?Gly?Leu?Arg?Leu?Leu?Gly?Ala?Arg?Ala?Arg?Gly

385 390 395 400

Val?Ala?Met?Leu?Gly?Val?Phe?Leu?Val?Ser?Ala?Val?Ala?His?Glu?Tyr

405 410 415

Ile?Phe?Cys?Phe?Val?Leu?Gly?Phe?Phe?Tyr?Pro?Val?Met?Leu?Ile?Leu

420 425 430

Phe?Leu?Val?Ile?Gly?Gly?Met?Leu?Asn?Phe?Met?Met?His?Asp?Gln?Arg

435 440 445

Thr?Gly?Pro?Ala?Trp?Asn?Val?Leu?Met?Trp?Thr?Met?Leu?Phe?Leu?Gly

450 455 460

Gln?Gly?Ile?Gln?Val?Ser?Leu?Tyr?Cys?Gln?Glu?Trp?Tyr?Ala?Arg?Arg

465 470 475 480

His?Cys?Pro?Leu?Pro?Gln?Ala?Thr?Phe?Trp?Gly?Leu?Val?Thr?Pro?Arg

485 490 495

Ser?Trp?Ser?Cys?His?Thr

500

<210>3

<211>18

<212>DNA

＜213〉synthetic

<220>

<22l>misc_feature

<222>(1)..(18)

＜223〉primer C41

<400>3

ggagaccgca?ccatggag 18

<210>4

<211>27

<212>DNA

＜213〉synthetic

<220>

<221>misc_feature

<222>(1)..(27)

＜223〉primer C42

<400>4

tgtctagacc?tctaggtatg?gcaggac 27

<210>5

<211>20

<212>DNA

＜213〉synthetic

<220>

<221>misc_feature

<222>(1)..(20)

＜223〉primer C21

<400>5

ggaagagtat?cagcatgacg 20

Claims (15)

1. A human cholesteryl ester synthase-2b, characterized in that the protein is selected from the group consisting of: (a) protein with amino acid sequence of SEQ ID NO: 2, or its conservative variant protein, or its activity Fragments, or their active derivatives. (b) the amino acid sequence of SEQ ID NO: 2 undergoes one or more amino acid residue substitution, deletion or The protein derived from (a) formed by adding and having the function of human cholesteryl ester synthase-2b white. 2. human cholesteryl ester synthase-2b as claimed in claim 1, is characterized in that, it has the aminoacid sequence shown in SEQ ID NO:2. 3. An isolated polynucleotide, characterized in that it comprises a nucleotide sequence selected from the group consisting of: (a) polynucleotide encoding protein as claimed in claim 1 or 2; (b) A polynucleotide complementary to polynucleotide (a). 4. The polynucleotide of claim 3, wherein the polynucleotide encodes a protein having an amino acid sequence shown in SEQ ID NO:2. 5. The polynucleotide of claim 3, wherein the sequence of the polynucleotide comprises one selected from the group consisting of: (a) the sequence of positions 13-1521 in SEQ ID NO: 1; (b) The sequence of positions 1-1522 in SEQ ID NO:1. 6. A vector comprising the polynucleotide according to claim 3. 7. A host cell, characterized in that it contains the vector according to claim 6. 8. The host cell of claim 7, wherein said host cell is a mammalian cell. 9. The host cell according to claim 8, wherein said host cell is a mouse, rat or human cell. 10. A method for preparing a protein with human cholesteryl ester synthase-2b activity, characterized in that the method comprises: (a) cultivating the host cell according to claim 7 under conditions suitable for expressing human cholesteryl ester synthase-2b; (b) Isolating a protein having human cholesteryl ester synthase-2b activity from the culture. 11. An antibody capable of specifically binding to the human cholesteryl ester synthase-2b according to claim 1. 12. A pharmaceutical composition, characterized in that it contains a safe and effective amount of human cholesteryl ester synthase-2b according to claim 1, or the polynucleotide according to claim 3, and a pharmaceutically acceptable carrier . 13. The use of human cholesteryl ester synthase-2b according to claim 1 in screening or preparing medicines for treating cholesterol-related diseases. 14. Use of the polynucleotide according to claim 3 in screening or preparing drugs for treating cholesterol-related diseases. 15. A method for screening drugs for the treatment of cholesterol-related diseases, comprising the steps of: (a) Under conditions suitable for growth, cultivate host cells, the host cells contain the expression vector according to claim 6, the expression vector contains the polynucleotide according to claim 3 and can be combined with the polynucleotide An exogenous promoter operably linked, wherein the candidate substance is added to the culture medium or lysate or protein preparation of the first group of host cells and the candidate substance is not added to the culture medium or lysate or protein preparation of the second group of host cells ; (b) measuring the activity of the cholesterol ester synthase-2b described in claim 1 of the first group and the second group of host cells or lysate or protein preparation, wherein the enzyme activity of the first group of host cells or lysate or protein preparation Above and below the second group indicates that the candidate substance is a drug for the treatment of cholesterol-related diseases.

Images